Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Vifor Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

VFMCRP and Fresenius Kabi Expand Collaboration in Nephrology in China with Veltassa® Agreement

Contact the Supplier

Lead Product(s): Patiromer

Therapeutic Area: Nephrology Product Name: Veltassa

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Fresenius Kabi AG

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 19, 2020

Details:

Fresenius Kabi will have the exclusive right to distribute and sell Veltassa® across China. By bringing Veltassa® to China, VFMCRP and Fresenius Kabi will deliver a treatment that will enable patients to remain on RAASi therapy by managing their chronic hyperkalemia.